Literature DB >> 26405604

The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+ T cell responses.

Robert J Johnston1, Xin Yu1, Jane L Grogan1.   

Abstract

Success in eliciting tumor rejection by therapeutic blockade of T cell checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4, has spurred re-evaluation of additional receptors that regulate antitumor responses. Here we summarize our recent studies characterizing the role of co-inhibitory receptor TIGIT in antitumor and other chronic CD8+ T cell responses.

Entities:  

Keywords:  CD226; PD1; TIGIT; antibodies; cancer immunotherapy; virus

Year:  2015        PMID： 26405604      PMCID： PMC4570113          DOI： 10.1080/2162402X.2015.1036214

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering.

Authors:  Katharina F Stengel; Kristin Harden-Bowles; Xin Yu; Lionel Rouge; Jianping Yin; Laëtitia Comps-Agrar; Christian Wiesmann; J Fernando Bazan; Dan L Eaton; Jane L Grogan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-15       Impact factor: 11.205

2.  The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity.

Authors:  Noa Stanietsky; Hrvoje Simic; Jurica Arapovic; Amir Toporik; Ofer Levy; Amit Novik; Zurit Levine; Meirav Beiman; Liat Dassa; Hagit Achdout; Noam Stern-Ginossar; Pinhas Tsukerman; Stipan Jonjic; Ofer Mandelboim
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-07       Impact factor: 11.205

3.  Vstm3 is a member of the CD28 family and an important modulator of T-cell function.

Authors:  Steven D Levin; David W Taft; Cameron S Brandt; Christoph Bucher; Edward D Howard; Eric M Chadwick; Janet Johnston; Angela Hammond; Kristen Bontadelli; Daniel Ardourel; LuAnn Hebb; Anitra Wolf; Thomas R Bukowski; Mark W Rixon; Joseph L Kuijper; Craig D Ostrander; James W West; Janine Bilsborough; Brian Fox; Zeren Gao; Wenfeng Xu; Fred Ramsdell; Bruce R Blazar; Katherine E Lewis
Journal:  Eur J Immunol       Date:  2011-03-18       Impact factor: 5.532

4.  The TIGIT/CD226 axis regulates human T cell function.

Authors:  Ester Lozano; Margarita Dominguez-Villar; Vijay Kuchroo; David A Hafler
Journal:  J Immunol       Date:  2012-03-16       Impact factor: 5.422

5.  The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity.

Authors:  Chen Zhu; Ana C Anderson; Anna Schubart; Huabao Xiong; Jaime Imitola; Samia J Khoury; Xin Xiao Zheng; Terry B Strom; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2005-11-13       Impact factor: 25.606

6.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

7.  The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.

Authors:  Robert J Johnston; Laetitia Comps-Agrar; Jason Hackney; Xin Yu; Mahrukh Huseni; Yagai Yang; Summer Park; Vincent Javinal; Henry Chiu; Bryan Irving; Dan L Eaton; Jane L Grogan
Journal:  Cancer Cell       Date:  2014-11-26       Impact factor: 31.743

8.  T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.

Authors:  Man Li; Pengyan Xia; Ying Du; Shengwu Liu; Guanling Huang; Jun Chen; Honglian Zhang; Ning Hou; Xuan Cheng; Luyu Zhou; Peifeng Li; Xiao Yang; Zusen Fan
Journal:  J Biol Chem       Date:  2014-05-09       Impact factor: 5.157

9.  Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses.

Authors:  Nicole Joller; Ester Lozano; Patrick R Burkett; Bonny Patel; Sheng Xiao; Chen Zhu; Junrong Xia; Tze G Tan; Esen Sefik; Vijay Yajnik; Arlene H Sharpe; Francisco J Quintana; Diane Mathis; Christophe Benoist; David A Hafler; Vijay K Kuchroo
Journal:  Immunity       Date:  2014-04-17       Impact factor: 31.745

10.  The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells.

Authors:  Xin Yu; Kristin Harden; Lino C Gonzalez; Michelle Francesco; Eugene Chiang; Bryan Irving; Irene Tom; Sinisa Ivelja; Canio J Refino; Hilary Clark; Dan Eaton; Jane L Grogan
Journal:  Nat Immunol       Date:  2008-11-16       Impact factor: 25.606
  10 in total
  16 in total

1.  mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer.

Authors:  Constance Le Goux; Sophie Vacher; Géraldine Pignot; Mathilde Sibony; Nicolas Barry Delongchamps; Benoit Terris; Eliane Piaggio; Marc Zerbib; Diane Damotte; Ivan Bieche
Journal:  Oncoimmunology       Date:  2017-08-14       Impact factor: 8.110

2.  Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions.

Authors:  Feng Xu; Alexander Sunderland; Yue Zhou; Richard D Schulick; Barish H Edil; Yuwen Zhu
Journal:  Cancer Immunol Immunother       Date:  2017-06-16       Impact factor: 6.968

Review 3.  Novel Targets for the Treatment of Melanoma.

Authors:  Lara Ambrosi; Shaheer Khan; Richard D Carvajal; Jessica Yang
Journal:  Curr Oncol Rep       Date:  2019-11-06       Impact factor: 5.075

4.  TIGIT signalling pathway negatively regulates CD4+ T-cell responses in systemic lupus erythematosus.

Authors:  Lie Mao; Hongyan Hou; Shiji Wu; Yu Zhou; Juan Wang; Jing Yu; Xiaohui Wu; Yanfang Lu; Liyan Mao; Munyemana Jean Bosco; Feng Wang; Ziyong Sun
Journal:  Immunology       Date:  2017-02-20       Impact factor: 7.397

5.  PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function.

Authors:  Sarah Whelan; Eran Ophir; Maya F Kotturi; Ofer Levy; Sudipto Ganguly; Ling Leung; Ilan Vaknin; Sandeep Kumar; Liat Dassa; Kyle Hansen; David Bernados; Benjamin Murter; Abha Soni; Janis M Taube; Amanda Nickles Fader; Tian-Li Wang; Ie-Ming Shih; Mark White; Drew M Pardoll; Spencer C Liang
Journal:  Cancer Immunol Res       Date:  2019-01-18       Impact factor: 11.151

6.  TIGIT and Helios Are Highly Expressed on CD4+ T Cells in Sézary Syndrome Patients.

Authors:  Neha Jariwala; Bernice Benoit; Andrew V Kossenkov; Landon K Oetjen; Timothy M Whelan; Christine M Cornejo; Junko Takeshita; Brian S Kim; Louise C Showe; Maria Wysocka; Alain H Rook
Journal:  J Invest Dermatol       Date:  2016-09-01       Impact factor: 8.551

7.  CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function.

Authors:  Deepak Mittal; Ailin Lepletier; William C Dougall; Mark J Smyth; Jason Madore; Amelia Roman Aguilera; Kimberley Stannard; Stephen J Blake; Vicki L J Whitehall; Cheng Liu; Mark L Bettington; Kazuyoshi Takeda; Georgina V Long; Richard A Scolyer; Ruth Lan; Nathan Siemers; Alan Korman; Michele W L Teng; Robert J Johnston
Journal:  Cancer Immunol Res       Date:  2019-03-20       Impact factor: 11.151

8.  Metabolism of Immune Cells in the Tumor Microenvironment.

Authors:  Jin G Jung; Anne Le
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity.

Authors:  Xiao Hu; Xikui Liu; Jacques Moisan; Yahong Wang; Charles A Lesch; Chauncey Spooner; Rodney W Morgan; Elizabeth M Zawidzka; David Mertz; Dick Bousley; Kinga Majchrzak; Ilona Kryczek; Clarke Taylor; Chad Van Huis; Don Skalitzky; Alexander Hurd; Thomas D Aicher; Peter L Toogood; Gary D Glick; Chrystal M Paulos; Weiping Zou; Laura L Carter
Journal:  Oncoimmunology       Date:  2016-11-04       Impact factor: 8.110

10.  Identification and characterization of HPV-independent cervical cancers.

Authors:  Carolyn E Banister; Changlong Liu; Lucia Pirisi; Kim E Creek; Phillip J Buckhaults
Journal:  Oncotarget       Date:  2017-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.